AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlights
- Radiopharm has received approval from the Australian Ethics Committee to expand its PD-L1 nanobody (RAD204) phase 1 trial in several types of tumor.
- The ongoing Phase 1 first-in-human study aims to evaluate the safety and tolerability of 177Lu-RAD204 in patients with PD-L1-positive advanced solid tumors.
Radiopharm Theranostics (ASX:RAD) shares rose approximately 4% to AU$0.027 on Tuesday. This positive movement follows the announcement that the company has received approval from the Australian Ethics Committee to expand its PD-L1 nanobody (RAD204) Phase 1 Trial in multiple tumor types.
The ongoing Phase 1 first-in-human study aims to evaluate the tolerability and safety profile of 177Lu-RAD204 in patients with PD-L1-positive advanced solid tumors.
“The implications of including additional PD-L1 expressing tumor types beyond NSCLC in this study is far-reaching,” said Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. “Patients with five additional PD-L1 expressing tumor types are now eligible for this basket trial, supporting the potential of 177Lu-RAD204 for a tumor-agnostic indication and as an effective radioimmunotherapy based on a pan-tumor predictive biomarker. With RAD204, we hope to provide an alternative strategy that can improve clinical outcomes for patients with PD-L1 positive advanced cancers, while potentially preserving their quality of life.”
